Julie Janssen, Ph.D.

Consultant

Bio

  • Joined Pharmetheus in 2020, actively working in client projects
  • Expertise includes clinical pharmacology, model informed drug development, and pharmacometrics in therapeutic areas such as oncology
  • M.Sc. in Pharmacy (2016) and Ph.D. in Medicine (2020) from Utrecht University, The Netherlands
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Model-informed early clinical development of BI-1808, a novel monoclonal antibody to tumor necrosis factor receptor 2